Search

Alain D Baron

from San Diego, CA
Age ~72
Get Report
Also known as:
Marilyn M Baron, Marilyn W Baron, Marilyn A Baron, Marilyn Mary Baron, Marilyn E Baron, Maralyn M Baron, Alain D Dr, Marilyn Mary
Phone and address:
12863 Baywind Pt, San Diego, CA 92130
(858) 720-8502
Related to:
Lauren M Baron, 40R Julia, 38Julia R Baron, 38Todd R Manlove, 41M Lauren, 40
Connected to:
Adam S Baron, 50Alison S Baron, 56Allison N Baron, 50Alysia B Baron, 51Amalia L Baron, 54Andrea J Baron, 66Annette L Baron, 82Anthony J Baron, 54Bobby J Baron, 33Brandy L Baron, 39

Alain Baron Phones & Addresses

  • 12863 Baywind Pt, San Diego, CA 92130 (858) 720-8502 (858) 720-8503
  • 809 Arrowwood Dr, Carmel, IN 46033 (317) 575-9471

Work

Company: Elcelyx therapeutics Mar 2010 Position: President and chief executive officer

Education

School / High School: Medical College of Georgia 1978

Skills

Biotechnology • Pharmaceutical Industry • Entrepreneurship • Drug Development • Clinical Development • Clinical Trials • Drug Discovery • Diabetes • Biopharmaceuticals • Start Ups • Medical Devices • Research • Venture Capital • Oncology • Strategy • Commercialization • Pharmacology • Clinical Research • Technology Transfer • Mergers and Acquisitions • Corporate Development • Infectious Diseases • Regulatory Submissions • Lifesciences • Managed Care • Product Launch • Strategic Partnerships • Angel Investing • Healthcare • Neurology • Venture Financing • Medical Writing • Internal Medicine • Marketing Strategy • Social Media • Leadership • Biomarkers

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Diabetes, Metabolism & Endocrinology, 1985

Industries

Pharmaceuticals

Specialities

Endocrinology, Diabetes & Metabolism • Endocrinology & Metabolism

Professional Records

Medicine Doctors

Alain Baron Photo 1

Dr. Alain D Baron, San Diego CA - MD (Doctor of Medicine)

View page
Specialties:
Endocrinology, Diabetes & Metabolism
Endocrinology & Metabolism
Address:
11995 El Camino Real Suite 305, San Diego, CA 92130
Certifications:
Diabetes, Metabolism & Endocrinology, 1985
Internal Medicine, 1981
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Medical College of Georgia
Graduated: 1978
Medical School
Jewish Genl Hosp
Graduated: 1978
Medical School
U Colo Sch Med
Graduated: 1978
Medical School
Ucsd
Graduated: 1978
Alain Baron Photo 2

Alain Daniel Baron, San Diego CA

View page
Specialties:
Internal Medicine
Endocrinology and Metabolism
Endocrinology, Diabetes & Metabolism
Work:
Elcelys Therapeutics Inc
11995 El Camino Real, San Diego, CA 92130
Education:
Medical College of Georgia (1978)

Resumes

Resumes

Alain Baron Photo 3

Co-Founder And Chief Executive Officer

View page
Location:
2710 Sand Hill Rd, Menlo Park, CA 94025
Industry:
Pharmaceuticals
Work:
Elcelyx Therapeutics since Mar 2010
President and Chief Executive Officer
self employed since 2008
Consultant
Morgenthaler Ventures since Sep 2008
Entrepreneur In Residence
Essentialis Therapeutics Inc. since 2006
Independent Board member
Amylin Pharmaceuticals, Inc. 1999 - 2008
SVP Research
Education:
University of California, San Diego - School of Medicine 1983 - 1986
Mcgill University 1978 - 1981
Augusta University 1974 - 1978
Doctor of Medicine, Doctorates, Medicine Mcgill University 1971 - 1974
Bachelors, Bachelor of Science
Skills:
Biotechnology
Pharmaceutical Industry
Entrepreneurship
Drug Development
Clinical Development
Clinical Trials
Drug Discovery
Diabetes
Biopharmaceuticals
Start Ups
Medical Devices
Research
Venture Capital
Oncology
Strategy
Commercialization
Pharmacology
Clinical Research
Technology Transfer
Mergers and Acquisitions
Corporate Development
Infectious Diseases
Regulatory Submissions
Lifesciences
Managed Care
Product Launch
Strategic Partnerships
Angel Investing
Healthcare
Neurology
Venture Financing
Medical Writing
Internal Medicine
Marketing Strategy
Social Media
Leadership
Biomarkers

Business Records

Name / Title
Company / Classification
Phones & Addresses
Alain D. Baron
President
ELCELYX THERAPEUTICS, INC
Mfg Pharmaceutical Preparations
11995 El Camino Real SUITE 305, San Diego, CA 92130
12636 High Blf Dr, San Diego, CA 92130
(858) 344-2816
Alain D. Baron
President
Nazura Biohealth, Inc
Biotechnical Research Noncommercial
11995 El Camino Real, San Diego, CA 92130
11995 El Cam, San Diego, CA 92130
Alain Daniel Baron
Alain Baron MD
Internist
9360 Towne Ctr Dr, San Diego, CA 92121
Alain D. Baron
Vice President
Amylin Pharmaceuticals
Pharmaceuticals · Mfg of Pharmaceutical Preparations & Commercial Research · Mfg Pharmaceutical Preparations & Commercial Research · Internist · Pharmaceutical Research Labora · Pharmaceutical Preparations · Research & Development in Biotechnology · Commercial Physical Research
9625 Towne Ctr Dr, San Diego, CA 92121
9360 Towne Ctr Dr, San Diego, CA 92121
9360 Town Ctr Dr, San Diego, CA 92121
9373 Towne Ctr Dr, San Diego, CA 92121
(858) 552-2200, (858) 552-2214, (858) 552-2212, (479) 788-7087

Publications

Us Patents

Gip Analog And Hybrid Polypeptides With Selectable Properties

View page
US Patent:
8263545, Sep 11, 2012
Filed:
Aug 17, 2007
Appl. No.:
11/840921
Inventors:
Odile Esther Levy - San Diego CA, US
Alain D. Baron - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Michael R. Hanley - San Diego CA, US
Samuel Janssen - San Diego CA, US
Carolyn M. Jodka - San Diego CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - San Diego CA, US
Richard A. Pittner - San Diego CA, US
Christopher J. Soares - San Diego CA, US
Ved Srivastava - San Diego CA, US
Andrew A. Young - San Diego CA, US
Thao Le - San Diego CA, US
Assignee:
Amylin Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 38/00
A61P 3/10
US Classification:
514 11, 514 68, 514 117
Abstract:
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Exendin-4 To Treat Nonalcoholic Steatohepatitis And Nonalcoholic Fatty Liver Disease

View page
US Patent:
8389472, Mar 5, 2013
Filed:
Aug 21, 2006
Appl. No.:
12/063712
Inventors:
Alain D. Baron - San Diego CA, US
Dennis Kim - San Diego CA, US
David G. Maggs - San Diego CA, US
Matthew Wintle - San Diego CA, US
Assignee:
Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE
International Classification:
A61K 38/26
A61K 38/00
A61K 38/16
A61K 39/00
US Classification:
514 72, 514 74, 514 213, 4241851, 4241981, 530300, 530324
Abstract:
The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases.

Treatment Of Cardiac Arrhythmias

View page
US Patent:
8389473, Mar 5, 2013
Filed:
Mar 30, 2010
Appl. No.:
12/750575
Inventors:
David R. Hathaway - Lincoln NE, US
Alain D. Baron - San Diego CA, US
Assignee:
Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE
International Classification:
A61K 38/16
A61K 38/28
US Classification:
514 72, 4241981, 530308
Abstract:
Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.

Methods Of Treating Obesity With Two Different Anti-Obesity Agents

View page
US Patent:
8394765, Mar 12, 2013
Filed:
Nov 14, 2007
Appl. No.:
11/940317
Inventors:
Jonathan D. Roth - San Diego CA, US
Christen M. Anderson - Encinitas CA, US
Alain D. Baron - San Diego CA, US
Assignee:
Amylin Pharmaceuticals LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE
International Classification:
A61K 38/00
A61K 38/16
A61K 38/22
US Classification:
514 48, 514 11, 514 58, 514 68, 514 69, 514 213
Abstract:
Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.

Gip Analog And Hybrid Polypeptides With Selectable Properties

View page
US Patent:
8404637, Mar 26, 2013
Filed:
Feb 10, 2006
Appl. No.:
11/816095
Inventors:
Odile Esther Levy - San Diego CA, US
Alain D. Baron - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Michael R. Hanley - San Diego CA, US
Samuel Janssen - San Diego CA, US
Carolyn M. Jodka - San Diego CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - San Diego CA, US
Richard A. Pittner - San Diego CA, US
Christopher J. Soares - San Diego CA, US
Ved Srivastava - San Diego CA, US
Andrew A. Young - San Diego CA, US
Assignee:
Amylin Pharmaceuticals, LLC - San Diego CA
International Classification:
A61K 38/00
A61P 3/10
US Classification:
514 72, 514 68
Abstract:
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Dpp-Iv Resistant Gip Hybrid Polypeptides With Selectable Properties

View page
US Patent:
8497240, Jul 30, 2013
Filed:
Aug 17, 2007
Appl. No.:
12/377856
Inventors:
Odile Esther Levy - San Diego CA, US
Alain D. Baron - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Michael R. Hanley - Corte Madera CA, US
Samuel Janssen - San Marcos CA, US
Carolyn M. Jodka - Encinitas CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - Del Mar CA, US
Richard A. Pittner - Palo Alto CA, US
Christopher J. Soares - La Jolla CA, US
Ved Srivastava - Cary NC, US
Andrew A. Young - Chapel Hill NC, US
Thao Le - Carlsbad CA, US
Assignee:
Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE
International Classification:
A61K 38/00
A61K 38/16
A61K 38/26
US Classification:
514 69, 514 213, 514 72, 514 117, 530324, 530308
Abstract:
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Compositions For The Treatment And Prevention Of Nephropathy

View page
US Patent:
20040209803, Oct 21, 2004
Filed:
Dec 19, 2003
Appl. No.:
10/741534
Inventors:
Alain Baron - San Diego CA, US
David Hathaway - Lincoln NE, US
Mahesh Mistry - Pepperell MA, US
Richard Roman - Brookfield WI, US
International Classification:
A61K038/26
US Classification:
514/012000
Abstract:
Compositions and methods for the prevention and treatment of nephropathy, including hypertensive and diabetic nephropathy, and nephropathy associated with insulin resistance and metabolic syndrome are described. Compositions of the invention include a compound that binds to a receptor for the glucagon like peptide-1, an incretin, a glucagon-like peptide-1 (GLP1), an exendin, or an analog (including an agonist analog), derivative, or variant of any of them.

Prevention And Treatment Of Cardiac Arrhythmias

View page
US Patent:
20040266683, Dec 30, 2004
Filed:
Dec 17, 2003
Appl. No.:
10/740146
Inventors:
David Hathaway - Lincoln NE, US
Alain Baron - San Diego CA, US
International Classification:
A61K038/26
A61K031/70
US Classification:
514/012000, 514/023000
Abstract:
Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.

Isbn (Books And Publications)

Diabetes Mellitus Manual

View page
Author

Alain Baron

ISBN #

0071431292

Ellenberg & Rifkin's Diabetes Mellitus: Theory and Practice

View page
Author

Alain Baron

ISBN #

0838521789

Control profile
Alain D Baron from San Diego, CA, age ~72 Get Report